A regulatory requirement non-interventional study to monitor the safety and effectiveness of Glyxambi (empagliflozin/linagliptin, 10/5mg, 25/5mg) in Korean patients with type 2 diabetes mellitus First published 06/12/2021 Last updated 02/07/2025 EU PAS number:EUPAS44579 Study Finalised